Connect with us

Cannabis News

White House Drug Strategy Shows Trump Administration’s Conflicts On Marijuana And Other Issues, Experts Say

Published

on

“On the one hand, the administration is moving in the direction of liberalizing access to cannabis, but at the same time, in the strategy, it talks about the risks of doing so.”

The White House’s newly released strategy to combat the nation’s drug and addiction crisis calls for some ambitious public health approaches that some experts say are laudable but will be hindered by the administration’s actions.

195 wide pages National Strategy for Drug Controlpublished on May 4, advocates making access to treatment easier than obtaining drugs, preventing young people from developing addictions in the first place, increasing support for people in recovery and reducing overdose deaths.

These broad goals are widely supported by public health researchers, addiction treatment clinicians, and recovery advocates.

But meeting such goals will be difficult for the administration mass layoffs of federal workers, cancel the investigation and community grants, attacks on institutions and practices which are useful for people who use drugs, and Medicaid cutsa state-federal health insurance program that is the nation’s largest payer of addiction and mental health care for low-income people.

Many of the components of the National Drug Control Strategy are “things that we would agree to and fully support”. Libby Joneswho leads overdose prevention efforts at the Global Health Advocacy Incubator, a public health advocacy group.

But “there are disconnects in terms of what’s important to the strategy and then what they’re actually going to fund,” he said of the Trump administration. “These inconsistencies are felt particularly loudly in this strategy.”

The White House’s National Drug Control Strategy has been released every two yearsit is a document that aims to define a coordinated approach to the federal government that has been one of the country’s defining issues in recent decades.

since 2000, More than 1.1 million people they have died of drug overdoses. Despite the deaths has decreased recentlythe number continues to rise compared to previous decades, and research suggests Overdose death rates for black Americans and Native Americans are disproportionately high.

The strategy document released this week is the first of President Donald Trump’s current term. In keeping with the administration’s approach to addiction issues, it places a strong emphasis on law enforcement efforts to reduce the supply of illegal drugs. The document repeatedly refers to a “war” against foreign “terrorist organizations” — the Trump administration’s term for drug cartels — and increased enforcement at US borders.

Also determines plans implementing artificial intelligence technologies to analyze illegal drugs brought into the country and wastewater testing to detect illegal drug use nationwide.

The second half of the strategy focuses on reducing the demand for drugs, supporting public health prevention efforts, addiction treatment, and helping people in recovery. Religion promotes the role of recovery and the widespread use of overdose reversal drugs such as naloxone.

In a news release, the White House Office of National Drug Control Policy called the document a “road map” that will “continue to dismantle our nation’s drug supply and defeat the scourge of illegal drugs.”

The Trump administration did not respond to requests for comment on how the strategy fits with its other actions.

In December, Trump signed one Reauthorization of the HELP Actcontinues with various treatment and recovery-related subsidies and the requirement that Medicaid cover all FDA-approved medications for opioid use disorders. He announced in January The Great American Recovery Initiativeincluding a 100 million dollar investment to combat homelessness, opioid addiction and public safety.

However, few details have been released about the initiative, and in January, about a month after the HELP Act was passed, billions of dollars in addiction-related grants suddenly became available. finish and reset In a frantic 24-hour period.

This “whirlwind” left a “sense of instability and uncertainty in the area”. Yngvild OlsenNational consultant for Manatt Health consulting. He led substance use treatment policy at the Substance Abuse and Mental Health Services Administration, or SAMHSA, under the Biden administration and left about six months into Trump’s second term.

Insecurity increased the president’s 2027 budget requestwhich proposes cutting various addiction and mental health programs and consolidating key federal agencies that work on these issues. Jones’ team and about 100 others in the field have done it he signed a letter Asking Congress to reject the proposals, as they did with similar requests last year.

The national drug strategy adds new and contradictory information to this confusing landscape.

Increasing access to treatment

One of the most significant public health goals in the strategy, mentioned at least half a dozen times, is to make treatment easier than buying illegal drugs.

National data underscores the need for: more than 80% of Americans those who need substance use treatment do not receive it.

The administration’s actions regarding health insurance may make it difficult to improve this statistic.

It’s Medicaid primary source of health coverage for adults with opioid use disorder. When implemented, the Medicaid work requirement in Trump’s One Big Beautiful Bill Act is expected to eliminate that coverage. About 1.6 million people with substance use disorders.

The last time the Medicaid rolls were purged was after that covid-era protections have expired – Many people who were receiving drugs for opioid addiction stopped and fewer people started treatment, according to one. research published last year.

Olsen, who is also an addiction medicine doctor, said she loves the strategy’s focus on making treatment readily available to anyone who wants it. But he said that’s “hard to really imagine when people might have to pay for it themselves because they might lose their Medicaid insurance coverage.”

Appreciate an analysis The upcoming Medicaid changes could cause 156,000 people to lose access to opioid use disorder medication and cause 1,000 more fatal overdoses a year.

People with private insurance may also be affected.

The Trump administration has he refused to enforce it Addressing the regulations of the Biden era strengthening mental health paritythe idea that insurance should cover mental illness and addiction treatment in comparison to physical treatments. And recently, the administration said that redo those regulations in total, raising fears that addiction treatment may become increasingly affordable.

The administration did not respond to specific questions about how it reconciles Medicaid and equity action with the goal of increasing treatment.

Prioritizing prevention

The strategy highlights that preventing addictions before they start is one of the keys to reducing drug demand. It calls for “promoting a drug-free America as the social norm” and implementing science-backed school and community-based programs.

“Investing in early prevention, before drug use starts, saves lives and resources,” he says, citing. several studies about cost effectiveness among such programs.

However, the president’s budget proposes cuts to these types of programs, and federal layoffs have decimated the agencies that would implement this work.

of the White House final quote request He proposes to cut approximately $220 million from SAMHSA Center for Substance Abuse Prevention and almost 40 million dollars Drug-free communities the program

Since the new administration began, SAMHSA has lost about half of the workforceand the Centers for Disease Control and Prevention about a quarter.

“It’s not clear to me that they’re going to have the funds or the people to make it happen,” Olsen said of the strategy’s prevention goals.

The strategy presents another wrinkle in the marijuana debate. The document points to marijuana use as one of the drivers of drug use disorders and “convergent evidence from multiple sources” suggests that cannabis use increases the risk of psychosis. It requires the development of new tools to treat marijuana withdrawal and addiction.

However, just two weeks ago, the White House led to reclassification medical marijuana is moving to and from a lower level of scheduled substances audition to do the same with marijuana.

“The administration, on the one hand, is moving in the direction of liberalizing access to cannabis,” Jones said, “but at the same time, strategically, it’s talking about the dangers of doing that.”

“There’s a disconnect there that begs the question: who do you think you are?” he added.

The administration did not respond to specific questions about its marijuana policies.

Stopping overdose deaths

One of the most surprising elements of the National Drug Control Strategy comes in the last paragraph of the last chapter. It focuses on public drug testing programs, which often use test strips to help people who use drugs determine whether their purchased lot contains more dangerous substances, such as fentanyl or xylazine. This helps them determine whether or not to use these drugs safely.

“Rapid test strips and similar technologies that detect fentanyl and other drugs are an important tool that should be legalized,” the strategy document says.

However, SAMHSA announced a last letter He said he would no longer pay for the test strips as part of the Trump administration’s “harm reduction and move away from practices that facilitate illegal drug use.”

The administration has also attacked harm reduction programs executive order and his the budget requests. He did not respond to specific questions about how that position affects the drug control strategy.

Regina LaBelleThe Georgetown University professor, who served as acting director of the Office of National Drug Control Policy in the Biden administration, wrote about the contradiction. a blog post: “It is the height of rhetoric over reality to defend an instrument while at the same time cutting off the funding used to acquire it.”

KFF Health News It is a national newsroom that produces in-depth journalism on health issues and is one of the core program drivers of KFF, an independent source of health policy research, surveys and journalism. Learn more KFF.

This the article appeared for the first time KFF Health News and is republished here under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Continue Reading

Cannabis News

Redefining the standards of UK cannabis

Published

on

By

Dalgety Ltd has entered into a partnership with Curaleaf Laboratories to supply pharmaceutical grade cannabis medicines to the UK cannabis market. The arrangement combines Dalgety’s cultivation operations, which are certified to EU-GMP standards, with Curaleaf Laboratories’ pharmaceutical manufacturing and distribution capabilities. According to the companies, this creates a UK-based supply route that does not rely on imported cannabis flowers, as Dalgety cultivates its product in-house. Dalgety claims it was the first company in the UK to grow, manufacture and supply EU-GMP medical cannabis from a single site.

© Curaleaf Laboratories

The growing facility, which is more than 30,000 square feet, is located indoors and uses hydroponic growing methods along with automated lighting, irrigation, humidity and temperature control systems. The company reports that it uses AI-assisted environmental monitoring, which extends the traceability of batches to the final product and compares them to operating standards for air filtration systems. Post-harvest processing is said to follow EU-GMP protocols, including microbial and cannabinoid testing.

The stated goal of this approach is to reduce between-harvest variation in terms of THC and CBD content, terpene profiles, and microbial safety. Dalgety says his cultivation is overseen by staff with experience in horticulture and biochemistry, some of whom have worked on cannabis cultivation projects internationally.

Through a partnership with Curaleaf Laboratories, Dalgety’s UK-grown cannabis is processed and distributed through a UK-based supply chain, rather than imported from overseas. Companies suggest that this arrangement can shorten the time it takes to get products to market compared to importing, and reduce the likelihood of supply disruptions. Because Dalgety and Curaleaf Laboratories are involved in cultivation, manufacturing and distribution, the companies say this oversees the product at every stage, making it clearer for prescribers to see where and how the product was made.

© Curaleaf Laboratories

Dalgety operates to EU-GMP standards and has been subject to regulatory review by the MHRA and the Home Office. Its operations include environmental monitoring, microbial testing, stability testing, controlled drying and curing procedures and quality assurance processes, along with controlled and secure facilities.

The company describes its work as controlled environment farming, hydroponic systems, environmental control technology, and efforts to stabilize cannabis genetics and phenotypes for batch-to-batch consistency.

© Curaleaf Laboratories

Dalgety has also opened its cultivation facilities for visits to healthcare professionals, clinicians, pharmacists, researchers and other industry stakeholders. The company says this is in response to the fact that much of the cannabis historically supplied to UK patients has been grown overseas, which has limited opportunities for UK clinicians to see first-hand the cultivation and quality control processes. These tours aim to provide visitors with information on cultivation standards, EU-GMP compliance procedures, environmental control systems, testing processes and the regulatory framework governing cannabis manufacturing in the UK.

Dalgety and Curaleaf Laboratories describe their partnership as expanding access to UK-grown medical cannabis, improving supply chain reliability and helping to meet sector regulations, placing it in the wider context of growing demand for cannabis-based treatments from UK patients.

For more information:
Curaleaf Laboratories
Email: (email protected)
https://curaleaflaboratories.co.uk/

Continue Reading

Cannabis News

Arkansas GOP Governor And Democratic Challenger Agree On Opposing Marijuana Legalization

Published

on

By

“Giving more access to drugs, especially recreational access, does nothing to help or benefit Arkansans.”

Antoinette Grajeda, Arkansas attorney

Contains medical marijuana It generated more than $1 billion since Arkansas voters legalized it in 2016

After the state opened its first dispensary in 2019, thousands of Arkansans joined the program and spent a record $291.1 million on medical marijuana in 2025, according to the state Department of Finance and Administration.

Tax revenue from those sales now supports free breakfast for public school students after lawmakers passed legislation last year.

Medical marijuana programs have expanded across the country, as has recreational marijuana. Two dozen states, including neighboring Missouri, allow recreational marijuana use, according to state legislatures.

Arkansas voters rejected an effort to legalize recreational marijuana in 2022despite the national teams spending millions in support of the measure.

Restrictions on marijuana have been relaxed at the federal level, and the US Department of Justice earlier this year downgraded the drug classification of medicinal cannabis.

Here’s what Arkansas’ gubernatorial candidates — Democratic State Sen. Fred Love, Republican Gov. Sarah Huckabee Sanders and Libertarian Colt Shelby — have to say about legalizing recreational marijuana.

Democratic State Sen. Fred Love

Love said he opposes legalization during a debate at the Arkansas Press Association’s annual conference in June.

Sitting in a crosswalk at her daughter’s school, Love said “marijuana is all over” as the children exited their vehicles. When you grow up in a community where recreational marijuana is present, you see that it doesn’t always have a positive effect, he said.

“I don’t think it’s something I support,” Love said. “I’ve seen the long-term impact.”

While he doesn’t personally support it, Love said he would support legalizing recreational marijuana if Arkansans voted on it.

Libertarian Colt Shelby

Shelby said he’s for whatever Arkansans want, so he would support legalizing recreational marijuana if voters approve.

Shelby said the state’s elected officials have forgotten what matters most is what Arkansans want, which is why she’s running for office.

Although Shelby says she doesn’t smoke weed herself, she says almost everyone knows it and she has the meds.

“It brings a lot of good things, so I won’t say that I’m against it, but let the people decide”, he said in the debate in June.

Republican Governor Sarah Huckabee Sanders

Sanders did not participate in the June debate, but said in an emailed statement that he does not support the legalization of recreational marijuana.

“Giving more access to drugs, especially recreational access, does nothing to help or benefit Arkansans,” Sanders said.

Sanders vetoed a law passed by the Legislature last year dispensaries have been allowed to deliver orders via a delivery vehicle or drive-through window.

The governor signed into law in 2023 the bill protecting the rights for medical marijuana patients and caregivers to obtain a license to carry a concealed handgun.

In 2025, Sanders backed that uses medical marijuana revenue to support free breakfast for all public school students.

This story was first published by the Arkansas Advocate.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Will the top World Cup expert in the fruit, vegetable, and horticulture sector come from Canada, the U.S. or Belgium?

Published

on

By






FreshPublishers 2026 World Cup Group Stage






The World Cup is coming to an end, with the third-place play-off between France and England on Saturday, and the final between Spain and Argentina the following day. It won’t be long until the grand winner of FreshPublishers’ first World Cup pool is revealed.

© Fresh Publishers

As previously reported, Slim Kooli from Courchesne Laros is the favorite to win the €1,000 prize. He has secured a comfortable lead over Nol Batist of North American Interstate Greenhouse Company, while buyer Bjorn Van Ryckeghem of Deprez Construct is currently in third place.

1 Sim School Spain 1–0 2–1 737 9716
2 Nol Batist France 2–1 1–1 674 9433
3 Bjorn Van Ryckeghem France 2–2 3–1 674 9264
4 Christian Anton Smedshaug England 1–2 1–2 659 9134
5 Perry Springintveld Spain 1–1 2–1 647 9105
6 Willem Tijssen Spain 2–0 2–1 710 9098
7 Hans Borsboom Spain 2–1 2–1 528 9058
8 Bart Triemstra Spain 2–1 2–1 737 9052
9 Youness Bensaid Spain 2–1 1–1 722 8954
10 Vijay Dijkstra Portugal 2–0 2–1 382 8953

However, there have been some surprises during the tournament, and bonus points must be added, so we will keep the suspense a little longer. On Monday we will find out who is the main World Cup announcer in the international fruit, vegetable and horticulture sector…



Publication date:













Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media